Shilpa Medicare concludes USFDA inspection at Telangana facility with one minor observation

31 Jul 2017 Evaluate

Shilpa Medicare has successfully completed inspection carried out by the United States Food and Drug Administration (USFDA) at its formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India with one minor observation. The inspection was carried out between July 24 and July 28, 2017.

The company is in the process of submission of corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

319.85 -0.65 (-0.20%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×